• NSCLC: adjuvant TKI therapy more beneficial in stage IIIa disease

    Meta-analysis finds no significant survival benefit in stage I disease.

  • NSCLC surgery: vein-first ligation cuts CTCs, improves survival

    Prospective randomized trial compares vein-first vs artery-first techniques.

  • Squamous NSCLC: low-dose gemcitabine schedule offers effective alternative

    Infusion takes longer but could reduce treatment cost.

  • ESTRO 2019 – Radical hemi-thoracic radiotherapy: a new standard of care for malignant pleural mesothelioma?

    According to the results of a randomised phase 3 trial, a high dose of radical hemi-thoracic radiotherapy significantly improves overall survival when compared to palliative radiotherapy

  • Durvalumab approved for lung cancer in Cancer Drugs Fund

    NICE was concerned about aspects of the evidence

  • ESTRO 2019 – Locally advanced NSCLC: safe to reduce PTV-margins and radiation dose to involved lymph nodes

    A reduction of PTV-margins and radiotherapy dose to the involved mediastinal lymph nodes in these patients resulted in a lower incidence of severe toxicity and a better overall survival.

  • Stage IB NSCLC: no benefit for chemotherapy after complete resection

    Guidelines offer conflicting recommendations on ACT necessity.

  • The probability of cancer in lung nodules in a UK population
    The probability of cancer in lung nodules in a UK population

    Findings from the UK Lung Cancer Screening trial.

  • NSCLC: frontline chemo + immunotherapy combination best in meta-analysis

    Meta-analysis suggests combination is best for frontline treatment of advanced disease.

  • Left-sided NSCLC: 4L node dissection yields survival benefit in select patients

    Survival benefits observed in stage II, IIIA, and N2 disease.

  • Cancer tied to suicide risk, particularly in first 4 years

    Analysis accounted for prediagnosis use of psychiatric care.

  • NSCLC brain mets: no benefit for surgery before stereotactic radiosurgery

    Data show similar rates of local control, survival with and without surgery.

  • Better survival with oligometastatic than polymetastatic SCLC

    Disease progression in oligometastatic patients was usually local, suggesting a local plus systemic treatment option.

  • Better survival for N3 Stage III NSCLC with chemo+radiation

    Survival benefit also high for patients aged ≥70 years.

  • Load more